Cardiology

Top Medical News
“Inclisiran first” strategy yields greater LDL-C reduction in ASCVD patients
Elaine Soliven, 2 hours ago

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Web-based app to guide nonprescription use of statins a win in TACTiC trial
Jairia Dela Cruz, 12 hours ago
Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.
Standardized protocols for hypertension management need alignment
13 hours ago
There is no short supply of standardized treatment protocols (STPs) for hypertension across the globe, but many of these can be further improved through interventions targeting alignment with the latest evidence-based guidelines and engagement with multiple stakeholders, suggests a study.
Primary preventive ablation may prevent ICD interventions, arrhythmia-related hospitalizations
Audrey Abella, Yesterday
In individuals with ischaemic cardiomyopathy (ICM) and chronic total occlusion of an infarct-related artery (IRA-CTO), preventive ablation at the time of implantable cardioverter-defibrillator (ICD) intervention is associated with a decreased risk of appropriate ICD therapy or ventricular arrhythmia (VA)-related hospitalization, findings from the PREVENTIVE VT trial have shown.
A sock to detect diabetic, CV complications?
Audrey Abella, 2 days ago
A study presented at EHRA 2024 demonstrated the potential of a sock fitted with a ballistocardiogram (BCG) sensor to predict diabetic complications by identifying foot pressure distribution patterns, as well as to detect cardiovascular issues.
People with depression gain most CV benefits from physical activity
2 days ago
Individuals who engage in physical activities (PA) enjoy a reduced risk of cardiovascular disease (CVD), especially those suffering from depression, with a recent study showing that PA acts through the brain’s stress-related activity.
CPAP helps lower BP in patients with sleep apnoea
Stephen Padilla, 3 days ago
Blood pressure (BP) slightly decreases in patients with obstructive sleep apnoea who undergo continuous positive airway pressure (CPAP) therapy, as seen in a study. Such effect is marginally higher in those with above-average apnea-hypopnea index (AHI).
Special Reports
Product Highlight - LYPSTAPLUS
11 Apr 2024
Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet
fenofibrate, metabolic syndrome, statins, omega-3 fatty acids, MACE
05 Feb 2024
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Treating type 2 diabetes mellitus with G.R.A.C.E.
22 Jan 2024
A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.
Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncont
30 Nov 2023
Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Effective management of type 2 diabetes mellitus with a combination of metformin and empagliflozin in a patient with metaboli
01 Nov 2023
Metabolic Syndrome (MS) is linked to insulin resistance and a combination of five medical conditions that increase the risk of developing atherosclerotic cardiovascular disease (ASCVD). Obesity is independently associated with an increased incidence of diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease (CVD), and certain cancers. Early CVD protection is crucial in MS patients with Type 2 diabetes (T2DM). The use of empagliflozin/metformin for managing T2DM in MS improved fasting blood glucose levels and HbA1c, demonstrating the effectiveness of this combination in both ASCVD and CVD risk factors patients.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Oral anticoagulant therapy for acute VTE in obese patients
Adjunct Assistant Prof. Pankaj Kumar Handa, 03 Apr 2023
Although direct-acting oral anticoagulants (DOACs) are widely recommended for first-line treatment of venous thromboembolism (VTE), their use in obese patients remains controversial due to the limited representation of such patients in clinical trials. As the prevalence of obesity continues its upward trend, clinicians increasingly have to make treatment decisions for obese patients. MIMS Doctor interviewed Adjunct Assistant Professor Pankaj Kumar Handa, Senior Consultant at Tan Tock Seng Hospital, Singapore, to gain his perspectives on oral anticoagulation in obese patients.
EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute he
21 Mar 2023
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
Conference Reports
“Inclisiran first” strategy yields greater LDL-C reduction in ASCVD patients
Elaine Soliven, 25 Apr 2024

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Web-based app to guide nonprescription use of statins a win in TACTiC trial
Jairia Dela Cruz, 24 Apr 2024
Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.
Primary preventive ablation may prevent ICD interventions, arrhythmia-related hospitalizations
Audrey Abella, 23 Apr 2024
In individuals with ischaemic cardiomyopathy (ICM) and chronic total occlusion of an infarct-related artery (IRA-CTO), preventive ablation at the time of implantable cardioverter-defibrillator (ICD) intervention is associated with a decreased risk of appropriate ICD therapy or ventricular arrhythmia (VA)-related hospitalization, findings from the PREVENTIVE VT trial have shown.
A sock to detect diabetic, CV complications?
Audrey Abella, 22 Apr 2024
A study presented at EHRA 2024 demonstrated the potential of a sock fitted with a ballistocardiogram (BCG) sensor to predict diabetic complications by identifying foot pressure distribution patterns, as well as to detect cardiovascular issues.
Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia
Elaine Soliven, 19 Apr 2024

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Second-hand smoke may up risk of AF
Elvira Manzano, 13 Apr 2024
 Exposure to second-hand tobacco smoke may increase the risk of developing atrial fibrillation (AF), as shown in a population-based cohort study using the UK Biobank database.
Mandibular device on par with CPAP for BP lowering in OSA patients
Audrey Abella, 12 Apr 2024
In the CRESCENT trial, a mandibular advancement device (MAD) was noninferior to a continuous positive airway pressure (CPAP) machine for reducing 24-hr mean arterial blood pressure (MBP) in individuals with obstructive sleep apnoea (OSA), uncontrolled hypertension, and high cardiovascular (CV) risk.
Product Highlights
CME Modules